Interleukin-7 inhibits tumor-induced CD27 -CD28 - suppressor T cells: Implications for cancer immunotherapy

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 4975-4986

  Zhang, Yue ^c   Pfannenstiel, Lukas W ^b   Bolesta, Elzbieta ^c   Montes, Carolina L ^c   Zhang, Xiaoyu ^c   Chapoval, Andrei I ^c   Gartenhaus, Ronald B ^c   Strome, Scott E ^c   Gastman, Brian R ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CD27 ANTIGEN; CD28 ANTIGEN; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 2; INTERLEUKIN 7; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN MCL 1; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CD27- CD28+ T LYMPHOCYTE; CELL PROTECTION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIGENS, CD27; ANTIGENS, CD28; CELL LINE, TUMOR; GENES, BCL-2; HUMANS; INTERLEUKIN-7; NEOPLASMS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 79960991375     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3328     Document Type: Article

References (50)

1. Montes CL, Chapoval AI, Nelson J, Orhue V, Zhang X, Schulze DH, et al. Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Cancer Res 2008;68:870-9. (Pubitemid 351206765)
2. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005;175:7046-52. (Pubitemid 41598952)
3. - T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007;179:4323-34.
4. Vallejo AN. CD28 extinction in human T cells: altered functions and the program of T-cell senescence. Immunol Rev 2005;205:158-69. (Pubitemid 40780184)
5. Effros RB. Role of T lymphocyte replicative senescence in vaccine efficacy. Vaccine 2007;25:599-604. (Pubitemid 44856110)
6. + regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 2009;27:29-33.
7. Martinez-Escribano JA, Hernandez-Caselles T, Campillo JA, Campos M, Frias JF, Garcia-Alonso A, et al. Changes in the number of CD80(+), CD86(+), and CD28(+) peripheral blood lymphocytes have prognostic value in melanoma patients. Hum Immunol 2003;64:796-801. (Pubitemid 36927643)
8. Tsukishiro T, Donnenberg AD, Whiteside TL. Rapid turnover of the CD8(+)CD28(-) T-cell subset of effector cells in the circulation of patients with head and neck cancer. Cancer Immunol Immunother 2003;52:599-607. (Pubitemid 37268192)
9. + T-cell replicative senescence in human aging. Immunol Rev 2005;205:147-57.
10. + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 2005;105:241-50.
11. Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001;167:6869-76. (Pubitemid 33144179)
12. + T cells enables preservation of a naive repertoire. J Immunol 1998;161:5909-17.
13. + T cells: reversal by interleukin-12 stimulation. Blood 2003;101:3543-9.
14. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008;205:1701-14. (Pubitemid 351962032)
15. + T cells. Blood 2009;113:6619-28.
16. Pallard C, Stegmann AP, van Kleffens T, Smart F, Venkitaraman A, Spits H. Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity 1999;10:525-35. (Pubitemid 29262655)
17. Muller J, Sperl B, Reindl W, Kiessling A, Berg T. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem 2008;9:723-7.
18. Li WQ, Jiang Q, Khaled AR, Keller JR, Durum SK. Interleukin-7 inactivates the pro-apoptotic protein Bad promoting T cell survival. J Biol Chem 2004;279:29160-6. (Pubitemid 38915789)
19. Hahn-Windgassen A, Nogueira V, Chen CC, Skeen JE, Sonenberg N, Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005;280:32081-9. (Pubitemid 41361813)
20. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med 2001;194:1711-9. (Pubitemid 34028651)
21. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 1998;95:11211-6. (Pubitemid 28450107)
22. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006;21:749-60. (Pubitemid 43376126)
23. Han J, Goldstein LA, Gastman BR, Rabinovitz A, Rabinowich H. Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem 2005;280:16383-92. (Pubitemid 40616768)
24. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 2006;281:10153-63. (Pubitemid 43864551)
25. Huntington ND, Labi V, Cumano A, Vieira P, Strasser A, Villunger A, et al. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim sustains B lymphopoiesis in the absence of IL-7. Int Immunol 2009;21:715-25.
26. Whiteside TL. Immune responses to malignancies. J Allergy Clin Immunol 2010;125:S272-83.
27. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9. (Pubitemid 44547756)
28. Imamichi H, Sereti I, Lane HC. IL-15 acts as a potent inducer of CD4(+) CD25(hi) cells expressing FOXP3. Eur J Immunol 2008;38:1621-30.
29. + T cells, which are increased in active rheumatoid arthritis. Clin Immunol 2007;124:328-35.
30. Rochman Y, Spolski R, Leonard WJ. New insights intothe regulation ofT cells by gamma(c) family cytokines. Nat Rev Immunol 2009;9:480-90.
31. van Herpen CM, van der Laak JA, de Vries IJ, van Krieken JH, de Wilde PC, Balvers MG, et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 2005;11: 1899-909.
32. +T-regulatory cells. J Immunother 2006;29:313-9.
33. Moller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K, et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer 1998;77:1907-16.
34. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelievre JD, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009;119:997-1007.
35. Sereti I, DunhamRM, Spritzler J, Aga E, Proschan MA, Medvik K, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009;113:6304-14.
36. Pellegrini M, Calzascia T, Elford AR, Shahinian A, Lin AE, Dissanayake D, et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 2009;15:528-36.
37. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR, et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005;16:513-33. (Pubitemid 41022015)
38. Kittipatarin C, Khaled AR. Interlinking interleukin-7. Cytokine 2007;39:75-83. (Pubitemid 47446258)
39. - T cells is associated with decreased Akt (Ser473) phosphorylation. J Immunol 2007;178:7710-9.
40. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008;14:458-70.
41. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999;286:1741-4. (Pubitemid 129515882)
42. Mitsiades CS, Mitsiades N, Koutsilieris M. The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets 2004;4:235-56. (Pubitemid 38560073)
43. Breslin EM, White PC, Shore AM, Clement M, Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol 2005;144:791-800. (Pubitemid 40516119)
44. Wang CY, Kim HH, Hiroi Y, Sawada N, Salomone S, Benjamin LE, et al. Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal 2009;2:ra11.
45. Jung MS, Jin DH, Chae HD, Kang S, Kim SC, Bang YJ, et al. Bcl-xL and E1B-19K proteins inhibit p53-induced irreversible growth arrest and senescence by preventing reactive oxygen species-dependent p38 activation. J Biol Chem 2004;279:17765-71. (Pubitemid 38560543)
46. Nelyudova A, Aksenov N, Pospelov V, Pospelova T. By blocking apoptosis, Bcl-2 in p38-dependent manner promotes cell cycle arrest and accelerated senescence after DNA damage and serum withdrawal. Cell Cycle 2007;6:2171-7. (Pubitemid 47450419)
47. Woodland RT, Fox CJ, Schmidt MR, Hammerman PS, Opferman JT, Korsmeyer SJ, et al. Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood 2008;111:750-60.
48. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-703. (Pubitemid 351860862)
49. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4. (Pubitemid 32467048)
50. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.